Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer

Breast Cancer Research

Volumn 13, Issue 5, 2011, Pages

  Jankowitz, Rachel C ^a   Cooper, Kristine ^a   Erlander, Mark G ^b   Ma, Xiao Jun ^b   Kesty, Nicole C ^b   Li, Hongying ^b   Chivukula, Mamatha ^c   Brufsky, Adam ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b BioTheranostics Inc   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; BUB1 SPINDLE CHECKPOINT PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HOMEODOMAIN PROTEIN; HOXB13 PROTEIN, HUMAN; IL17RB PROTEIN, HUMAN; INTERLEUKIN RECEPTOR; MGCRACGAP; NEK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; BREAST CANCER INDEX; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CASE STUDY; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY ASSESSMENT; EARLY CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INSTRUMENT VALIDATION; INTERMEDIATE RISK PATIENT; INTERMETHOD COMPARISON; LOW RISK PATIENT; LYMPH NODE; MAJOR CLINICAL STUDY; MORTALITY RATE; OVERALL SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK ASSESSMENT; SOFTWARE; SURVIVAL PREDICTION; SURVIVAL RATE; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENETICS; MIDDLE AGED; MORTALITY; ONLINE SYSTEM; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GTPASE-ACTIVATING PROTEINS; HOMEODOMAIN PROTEINS; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ONLINE SYSTEMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, INTERLEUKIN; SURVIVAL RATE; TAMOXIFEN;

EID: 80053948631     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3038     Document Type: Article

References (26)

1. Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N: Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004, 364: 858-868. 10.1016/S0140-6736(04)16981-X.
2. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 2005, 23: 2716-2725.
3. Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J: Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J Clin Oncol. 2009, 27: 214-219. 10.1200/JCO.2008.17.3914.
4. Paik S, Tang G, Fumagalli D: An ideal prognostic test for estrogen receptor-positive breast cancer?. J Clin Oncol. 2008, 26: 4058-4059. 10.1200/JCO.2008.16.7528.
5. Bao T, Davidson NE: Gene expression profiling of breast cancer. Adv Surg. 2008, 42: 249-260.
6. Stal O, Jerevall PL, Ma XJ, Li H, Salunga R, Erlander M, Sgroi D, Holmlund B, Skoog L, Fornander T: Validation of prognostic utility of HOXB13:IL17BR and Molecular Grade Index in early stage breast cancer. Cancer Res. 2009, 69: 504s-(Abstract 577)
7. Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P, Sotiriou C, Erlander M, Sgroi D: A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res. 2008, 14: 2601-2608. 10.1158/1078-0432.CCR-07-5026.
8. Rutqvist LE, Johansson H: Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol. 2007, 46: 133-145. 10.1080/02841860601034834.
9. Wang Z, Dahiya S, Provencher H, Muir B, Carney E, Coser K, Shioda T, Ma XJ, Sgroi DC: The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer. Clin Cancer Res. 2007, 13: 6327-6334. 10.1158/1078-0432.CCR-07-0310.
10. Jerevall PL, Ma XJ, Li H, Salunga R, Kesty NC, Erlander MG, Sgroi DC, Holmlund B, Skoog L, Fornander T, Nordenskjold B, Stal O: Prognostic utility of HOXB13: IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer. 2011, 104: 1762-1769. 10.1038/bjc.2011.145.
11. Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA, Osborne CK, Allred DC, Erlander MG: The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006, 24: 4611-4619. 10.1200/JCO.2006.06.6944.
12. Adjuvant! Online homepage. [ http://www.adjuvantonline.com ]
13. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001, 19: 980-991.
14. Heagerty PJ, Zheng Y: Survival model predictive accuracy and ROC curves. Biometrics. 2005, 61: 92-105. 10.1111/j.0006-341X.2005.030814.x.
15. Heagerty PJ, Zeger SL: Multivariate continuation ratio models: connections and caveats. Biometrics. 2000, 56: 719-732. 10.1111/j.0006-341X.2000.00719.x.
16. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717.
17. Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thurlimann B, Senn HJ: First--select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol. 2006, 17: 1772-1776. 10.1093/annonc/mdl398.
18. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009, 20: 1319-1329. 10.1093/annonc/mdp322.
19. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ: Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008, 100: 1179-1183. 10.1093/jnci/djn233.
20. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med. 2009, 360: 790-800. 10.1056/NEJMra0801289.
21. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE, Wickerham DL, Wolmark N: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006, 24: 3726-3734. 10.1200/JCO.2005.04.7985.
22. Piccart-Gebhart MJ: New developments in hormone receptor-positive disease. Oncologist. 2011, 16 (Suppl 1): 40-50.
23. Haibe-Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, Van't Veer L, Piccart M, Bontempi G, Sotiriou C: Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics. 2008, 9: 394. 10.1186/1471-2164-9-394.
24. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C: Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007, 13: 3207-3214. 10.1158/1078-0432.CCR-06-2765.
25. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW, Perez EA, Shulman LN, Martino S, Sparano JA: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008, 26: 4063-4071. 10.1200/JCO.2007.14.4501.
26. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL, Shak S: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010, 28: 1829-1834. 10.1200/JCO.2009.24.4798.